SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma

Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC), yet resistance limits its efficacy. The Hedgehog (HH) signaling pathway contributes to drug resistance by maintaining HCC stem cell characteristics, but its role at the single-cell level is underexplored. Utilizing single-cell RNA sequencing (scRNA-seq) and machine learning, we identified solute carrier family 25 member 39 (SLC25A39) as a key regulator of the HH pathway. Analyses of various cohorts revealed that elevated SLC25A39 correlates with poor prognosis in HCC patients. SLC25A39 knockdown inhibited cancer stem cell characteristics and reduced sorafenib resistance in vitro. Furthermore, combined SLC25A39 suppression and sorafenib treatment significantly hindered HCC progression in both in vitro and in vivo models. These findings highlight the potential of shSLC25A39 to enhance sorafenib sensitivity , presenting a new avenue for combating drug resistance and enhancing therapeutic effectiveness.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2025-10-15
DOI
https://doi.org/10.1038/s41598-025-20008-7
Citations
1
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.94
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma

Yuting Qian, Shiwei Zhu, Hang Yin, W. Sun et al.
1 citations
Scientific Reports
Cancer Genomics and Diagnostics
0.94
article

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma

Yuting Qian, Shiwei Zhu, Hang Yin, W. Sun, Jing Ke, Zihao Wu, Yufeng Gao, Jiatao Liu, Qian Qiu, Ying Dai, Hui Zhang, Qianqian Zhang, Lulu Zhang, Mengqi Zhao, Yanye Ruan, Wen Xu, Honghai Xu, Wei J. Wang
article en
1 citations

Abstract

Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC), yet resistance limits its efficacy. The Hedgehog (HH) signaling pathway contributes to drug resistance by maintaining HCC stem cell characteristics, but its role at the single-cell level is underexplored. Utilizing single-cell RNA sequencing (scRNA-seq) and machine learning, we identified solute carrier family 25 member 39 (SLC25A39) as a key regulator of the HH pathway. Analyses of various cohorts revealed that elevated SLC25A39 correlates with poor prognosis in HCC patients. SLC25A39 knockdown inhibited cancer stem cell characteristics and reduced sorafenib resistance in vitro. Furthermore, combined SLC25A39 suppression and sorafenib treatment significantly hindered HCC progression in both in vitro and in vivo models. These findings highlight the potential of shSLC25A39 to enhance sorafenib sensitivity , presenting a new avenue for combating drug resistance and enhancing therapeutic effectiveness.

Scientific ReportsVol. 15(1)
University of Science and Technology of China (CN), Anhui University (CN), Bengbu Medical College (CN), Anhui Medical University (CN), First Affiliated Hospital of Anhui Medical University (CN), First Affiliated Hospital of Bengbu Medical College (CN)
Openalex Percentile: Top 19%
Cancer Genomics and Diagnostics
0.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.